natgillin/translations-raw huggingface dataset:
A nitrogen-containing heterocyclic compound, a salt thereof, or an N-oxide compound thereof, according to Claim 1, wherein, in Formula (II), R represents a group represented by CR1R2R3, and R1 is an unsubstituted or substituted C1-8 alkyl group, R2 is an unsubstituted or substituted C1-8 alkyl group; and R3 is a substituted C1-8 alkyl group, an unsubstituted or substituted C2-8 alkenyl group, an unsubstituted or substituted C2-8 alkynyl group, an unsubstituted or substituted C3-8 cycloalkyl group, an unsubstituted or substituted C6-10 aryl group, an unsubstituted or substituted heterocyclic group, an unsubstituted or substituted C1-8 acyl group, an unsubstituted or substituted (1-imino)C1-8 alkyl group, an unsubstituted or substituted C1-8 alkoxycarbonyl group, an unsubstituted or substituted carbamoyl group, an unsubstituted or substituted sulfonyl group, or a cyano group; 
Heterociklički spoj koji sadrži dušik, njegova sol, ili njegov N-oksidni spoj, prema zahtjevu 1, naznačen time što, u Formuli (II), R predstavlja skupinu prikazanu s CR1R2R3, i je nesupstituirana ili supstituirana skupina C1-8 alkil, R2 je nesupstituirana ili supstituirana skupina C1-8 alkil; i R3 je supstituirana skupina C1-8 alkil, nesupstituirana ili supstituirana skupina C2-8 alkenil, nesupstituirana ili supstituirana skupina C2-8 alkinil, nesupstituirana ili supstituirana skupina C3-8 cikloalkil, nesupstituirana ili supstituirana skupina C6-10 aril, nesupstituirana ili supstituirana heterociklička skupina, nesupstituirana ili supstituirana skupina C1-8 acil, nesupstituirana ili supstituirana skupina (1-imino)C1-8 alkil, nesupstituirana ili supstituirana skupina C1-8 alkoksikarbonil, nesupstituirana ili supstituirana skupina karbamoil, nesupstituirana ili supstituirana sulfonil skupina, ili cijano skupina;
A method of decoding an image, the method comprising: extracting information about a maximum size of a coding unit, and split information indicating whether to split a coding unit of a depth i, where i is integer, into coding units of a depth i+1, from a bitstream including encoded data of the image; 
Postupak za dekodiranje slike, te postupak sadrži: izvlačenje informacija o maksimalnoj veličini jedinice kodiranja, i informacije o razdvajanju koja pokazuje da li treba podijeliti jedinicu kodiranja dubine i, gdje je i cijeli broj, u jedinice kodiranja dubine i+1, iz toka bitova uključujući kodirane podatke iz slike;
An antibody which is capable of binding to Interleukin 11 (IL-11) or IL-11 receptor a (IL-11Ra) and inhibiting IL-11 mediated signalling, for use in a method of treating or preventing a disease or condition characterised by fibrosis of an organ of the gastrointestinal system. 
Protutijelo, naznačeno time, da je sposobno za vezivanje na Interleukin 11 (IL-11) ili IL-11 receptor a (IL-11Ra) i za inhibiranje signalizacije posredovane s IL-11, pri čemu se upotrebljava u postupku liječenja ili prevencije fibroze kod čovjeka.
A compound of formula ((S,S)-SDG-1) or a compound of formula (R,R)-SDG-2 prepared by a process comprising: 
Postupak za pripremu spoja formule ((S,S)-SDG-1) ili spoja formule (R,R)-SDG-2 naznačeno time, da se postupak sastoji od:
The compound of claim 1, wherein said reacting of step (e) is carried out in the presence of a Lewis acid, such as TMSOTf. 
Postupak sukladno zahtjevu 1, naznačen time, što se navedena reakcija iz koraka (e) provodi u prisutnosti Lewis-ove kiseline, kao što je TMSOTf.
The compound of claim 1, wherein said cleaving is carried out in the presence of H2 and Pd/C in MeOH. 
Postupak sukladno zahtjevu 1, naznačen time, što se spomenuto otapanje provodi u MeOH u prisutnosti H2 i Pd/C.
The compound of claim 1, wherein said separation procedure is carried out using preparative thin layer chromatography. 
Postupak sukladno zahtjevu 1, naznačen time, što se spomenuti postupak odvajanja provodi korištenjem preparativne tankoslojne kromatografije.
The compound of claim 1, wherein said Stobbe condensation reaction is carried out in MeOH and in the presence of lithium. 
Postupak sukladno zahtjevu 1, naznačen time, što se spomenuta Stobbe-ova reakcija kondenzacije provodi u MeOH i u prisutnosti litija.
The compound of claim 7, wherein said lithium is in the form of lithium wires. 
Postupak sukladno zahtjevu 7, naznačen time, što je navedeni litij u obliku litijskih žica.
The compound of claim 1, wherein said compound of formula (4) is prepared by the process comprising reacting vanillin with methyl succinate via a Stobbe condensation reaction, followed by an esterification reaction. 
Postupak sukladno zahtevu 1, naznačen time, što se navedeni spoj formule (4) priređuje postupkom koji obuhvaća reakciju vanilina i metil sukcinatom putem Stobbe-ove kondenzacijske reakcije, nakon čega slijedi reakcija esterifikacije.
The compound of claim 9, wherein said Stobbe condensation reaction is carried out in MeOH and in the presence of lithium wires. 
Postupak sukladno zahtjevu 9, naznačen time, što se navedena Stobbe-ova kondenzacijska reakcija provodi u MeOH i u prisutnosti litijske žice.
A safety mechanism (16,25) as claimed in anyone of claims 1 to 3, wherein the receiver (360) is an electromagnetic receiver and the signal is an electromagnetic signal. 
Bunar (10) sukladno patentnom zahtjevu 1 i 2, naznačen time, da je prijemnik (360) ili primopredajnik elektromagnetski prijemnik ili primopredajnik (250, 360) respektivno i signal je elektromagnetski signal.
a compound which is a weak acid, which acid is presented in intimate mixture with the microparticles of alfentanil or salt thereof, by being presented either: within the carrier particles, such that said carrier particles comprise a composite of: 
spoj koji je slaba kiselina ili kelatno sredstvo/sredstvo sekvestracije, koji spoj je iskazan u bliskoj smjesi s mikročesticama alfentanila ili njegovom soli, tako što iskazuje čestice navedenog spoja unutar ili na površinama navedenih čestica nosača.
A composition for use as claimed in Claim 15 wherein the composition is administered not more than about 20 minutes prior to the procedure. 
Pripravak za uporabu kao što je definirano u zahtjevu 14, naznačen time da se pripravak primjenjuje ne više od oko 20 minuta prije navedenog postupka.
A well (10) as claimed in claim 1, wherein the wireless receiver (360) is one of: 
Bunar (10) sukladno patentnom zahtjevu 1, naznačen time, što je prijemnik (360) primopredajnik (250, 360).
A composition comprising Compound 2: 
Spoj 2: naznačen time što:
n is 1 or 2; X is hydrobromic acid, benzenesulfonic acid, camphor sulfonic acid, 1,2-ethane disulfonic acid, hydrochloric acid, maleic acid, methanesulfonic acid, naphthalene-2-sulfonic acid, 1,5-naphthalene disulfonic acid, oxalic acid, 4-toluenesulfonic acid or 2,4,6-trihydroxybenzoic acid; and 
n je 1 ili 2; i X je bromovodična kiselina, benzensulfonska kiselina, kamfor sulfonska kiselina, 1,2-etan disulfonska kiselina, klorovodična kiselina, maleinska kiselina, metansulfonska kiselina, naftalen-2-sulfonska kiselina, 1,5-naftalen disulfonska kiselina, oksalna kiselina, 4-toluensulfonska kiselina ili 2,4,6-trihidroksibenzojeva kiselina.
a lower through opening (493) at a lowermost portion (499) of the bottom plate (49). 
donji prolazni otvor (493) na najnižem dijelu (499) donje ploče (49).
The outlet basin (4) in accordance with claim 1, wherein the grating (47) comprises a plurality of ribs (471) oriented side by side. 
Izlazni bazen (4) u skladu sa zahtjevom 1, naznačen time što rešetka (47) sadrži mnoštvo rebra (471) koja su postavljena jedno uz drugo.
The outlet basin (4) in accordance with claim 1, wherein the bottom plate (49) comprises a fine-meshed material. 
Izlazni bazen (4) u skladu sa zahtjevom 1, naznačen time što donja ploča (49) sadrži fini mrežasti materijal.
The outlet basin (4) in accordance with claim 1, wherein the lower opening (493) leads into a second pipe socket (495) arranged to be sealingly connected to a second outlet hose (99). 
Izlazni bazen (4) u skladu sa zahtjevom 1, naznačen time što donji otvor (493) vodi u drugu utičnicu za crijevo (495) koja je postavljena tako da je brtveno spojena na drugo izlazno crijevo (99).
A feed containing conventional feed ingredients and conventional additives and other auxiliary agents, characterized in that the feed contains inside and on the surface of feed raw material particles a fatty acid mixture in which the content of saturated fatty acids is more than 90% and the feed comprises an emulsifier, wherein the amount of emulsifier is 0.01-1.0% by weight of the feed. 
Krmna smjesa za preživače, naznačena time što, dodatno uz uobičajene sirove materijale hrane koji uključuju materijale koji sadrže bjelančevine, ugljikohidrate i masti, hrana sadrži unutar i na površini čestica sirovog materijala hrane mješavinu masnih kiselina, pri čemu je udio slobodne palmitinske kiseline barem 90% i ukupni udio mješavine masnih kiselina u spomenutoj hrani za preživače je viši od 10% masenog udjela.
The insulation block according to claim 1 or 2, characterized in that the distance between the large surfaces of the insulation block from each other is 20 to 600 mm, or 50 to 400 mm. 
Izolacijski blok prema zahtjevu 4, naznačen time što je udaljenost među velikih površina izolacijskog bloka, kao što je izolacijska ploča, jedna od druge 20 do 600 mm, ili 50 do 400 mm.
A method for identifying a subject at risk for or having a plasma kallikrein (pKal)-mediated disorder, the method comprising: 
Postupak za identificiranje subjekta koji ima rizik od razvoja, ili koji ima poremećaj posredovan kalikreinom u plazmi (pKal), naznačen time što postupak sadrži:
and wherein the pKal-mediated disorder is hereditary angioedema (HAE), rheumatoid arthritis, ulcerative colitis, or Crohn's disease. 
i pri čemu poremećaj posredovan s pKal je nasljedni angioedem (HAE), reumatoidni artritis, ulcerativni kolitis ili Crohnova bolest.
The method of any one of claims 1-2, wherein the levels of the cleaved HMWK and optionally intact HMWK are measured by a detection agent, which specifically binds cleaved HMWK as compared to intact HMWK, or specifically binds intact HMWK as compared to cleaved HMWK, wherein optionally the detection agent does not bind low molecular weight kininogen (LMWK). 
Postupak prema bilo kojem od zahtjeva 1-2, naznačen time što se razine cijepanog HMWK i proizvoljno intaktnog HMWK mjere sa sredstvom za detekciju, koje specifično veže cijepani HMWK u usporedbi s intaktnim HMWK, ili specifično veže intaktni HMWK u usporedbi s cijepanim HMWK, pri čemu proizvoljno sredstvo za detekciju ne veže kininogen male molekularne težine (LMWK).
The method of claim 3, wherein the detection agent is an antibody; preferably wherein the antibody specifically binds cleaved HMWK as compared to intact HMWK, and optionally, does not bind LMWK, more preferably wherein the detection agent is an antibody that binds to the C-terminus of the light chain of cleaved HMWK. 
Postupak prema zahtjevu 3, naznačen time što sredstvo za detekciju je protutijelo; poželjno naznačen time što protutijelo specifično veže cijepani HMWK u usporedbi s intaktnim HMWK, i proizvoljno, ne veže LMWK, poželjnije pri čemu je sredstvo za detekciju protutijelo koje se veže na C-terminalni kraj laganog lanca cijepanog HMWK.
The method of any one of claims 1 to 5, wherein the sample is a blood sample or a plasma sample. 
Postupak prema bilo kojem od zahtjeva 1 do 5, naznačen time što uzorak je uzorak krvi ili uzorak plazme.
The method of any of the preceding claims further comprising determining if the disorder is susceptible to treatment with a pKal inhibitor, wherein the disorder is susceptible to treatment with a pKal inhibitor if the value of cleaved HMWK is above the reference value. 
Postupak prema bilo kojem od prethodnih zahtjeva koji nadalje obuhvaća određivanje ako je poremećaj osjetljiv na liječenje s inhibitorom pKal, pri čemu je poremećaj osjetljiv na liječenje s inhibitorom pKal ako je vrijednost cijepanog HMWK iznad referentne vrijednosti.
A method for evaluating a treatment of a pKal-mediated disorder in a subject, the method comprising: 
Postupak za ocjenjivanje liječenja poremećaja posredovanog s pKal kod subjekta, naznačen time što postupak sadrži:
An immediate release pharmaceutical formulation in the form of a tablet, stock granulation, or capsule comprising: (1) an SGLT2 inhibitor selected from dapagliflozin and dapagliflozin (S) propylene glycol hydrate; (2) metformin hydrochloride; hydroxypropyl cellulose as a binder; microcrystalline cellulose as a filler; sodium starch glycolate or hydroxypropyl cellulose, low substituted as a disintegrant; and magnesium stearate as a lubricant. 
Farmaceutska formulacija s trenutnim oslobađanjem u obliku tablete, temeljnog standardnog granulata, ili kapsule koja sadrži: (1) SGLT2 inhibitor odabran od dapagliflozina i dapagliflozin (S) propilen glikol hidrata; (2) metformin hidroklorid; hidroksipropil celulozu kao vezivo; mikrokristalnu celulozu kao punilo; natrijev škrob glikolat ili hidroksipropil celuloze, nisko supstituirane kao sredstvo za raspadanje; i magnezijev stearat kao sredstvo za povećanje skliskosti.
The pharmaceutical formulation according to claim 1, in the form of a stock granulation. 
Farmaceutska formulacija prema zahtjevu 1, naznačena time što je u obliku temeljnog standardnog granulata.
The pharmaceutical formulation according to claim 1, in the form of a capsule. 
Farmaceutska formulacija prema zahtjevu 1, naznačena time što je u obliku kapsule.
0.8% dapagliflozin or dapagliflozin (S) propylene glycol hydrate; 69% metformin hydrochloride; 3% hydroxypropyl cellulose; 20% microcrystalline cellulose; 6.5% hydroxypropyl cellulose, low substituted; and 0.8% magnesium stearate; 
0.8% dapagliflozina ili dapagliflozin (S) propilen glikol hidrata; 69% metformin hidroklorida; 3% hidroksipropil celuloze; 20% mikrokristalne celuloze; 6.5% hidroksipropil celuloze, nisko supstituirane; i 0.8% magnezijevog stearata;
The pharmaceutical formulation according to claim 10 further comprising 19 mgs hydroxypropyl cellulose; 150 mgs microcrystalline cellulose; 60 mgs sodium starch glycolate; and 4.5 mgs magnesium stearate. 
Farmaceutska formulacija prema zahtjevu 10 naznačena time što dodatno sadrži 19 mg hidroksipropil celuloze; 150 mg mikrokristalne celuloze; 60 mg natrijev škrob glikolat; i 4.5 mg magnezijev stearat.
The pharmaceutical formulation according to claim 13 wherein the form is a tablet and there is a coating comprising polyvinyl alcohol, polyethylene glycol, titanium dioxide and talc. 
Farmaceutska formulacija prema zahtjevu 13 naznačena time što oblik je tableta i sadrži premaz koji sadrži polivinil alkohol, polietilen glikol, titanijev dioksid i talk.
The pharmaceutical formulation according to claim 20 wherein the form is a tablet and there is a coating comprising polyvinyl alcohol, polyethylene glycol, titanium dioxide, talc and yellow iron dioxide. 
Farmaceutska formulacija prema zahtjevu 20 naznačena time što oblik je tableta i sadrži premaz koji sadrži polivinil alkohol, polietilen glikol, titanijev dioksid, talk i žuti željezov oksid.
The pharmaceutical formulation according to any of claims 1-21 for use in treating a disorder or disease associated with SGLT2 activity that is diabetes (including type I and type II diabetes), impaired glucose tolerance, insulin resistance, nephropathy, retinopathy, neuropathy and cataracts, hyperglycemia, hyperinsulinemia, hypercholesterolemia, dyslipidemia, elevated blood levels of free fatty acids or glycerol, hyperlipidemia, hypertriglyceridemia, obesity, wound healing, tissue ischemia, atherosclerosis or hypertension in a mammal. 
Farmaceutska formulacija prema bilo kojem od zahtjeva 1-21 naznačena time što je za upotrebu za liječenje poremećaja ili bolesti povezane s aktivnošću SGLT2 koja je dijabetes (uključujući dijabetes tipa I i dijabetes tipa II), poremećenu toleranciju glukoze, otpornost na inzulin, nefropatija, retinopatija, neuropatija i katarakti, hiperglikemija, hiperinzulinemija, hiperkolesterolemija, dislipidemija, povišene razine slobodnih masnih kiselina ili glicerola u krvi, hiperlipidemija, hipertrigliceridemija, pretilost, zacjeljivanje rana, ishemija tkiva, ateroskleroza ili hipertenzija kod sisavaca.
The pharmaceutical formulation for use according to claim 22 wherein the disorder is type II diabetes and the mammal is a human. 
Farmaceutska formulacija za upotrebu prema zahtjevu 22 naznačena time što poremećaj je dijabetes tipa II i sisavac je čovjek.
mixing the granules with a filler and a disintegrant; 
miješanje granula s punilom i sredstvom za raspadanje;
further mixing with a lubricant to obtain a final mixture; 
daljnje miješanje sa sredstvom za povećanje skliskosti da se dobije konačna smjesa;
The method of claim 24 or claim 25, wherein the pharmaceutical formulation is 0.25-0.8% dapagliflozin or dapagliflozin (S) propylene glycol hydrate; 62-77% metformin hydrochloride; 3-10% hydroxypropyl cellulose; 5-21% microcrystalline cellulose; 5-9% sodium starch glycolate; and 0.6-1.4% magnesium stearate. 
Postupak prema zahtjevu 24 ili zahtjevu 25, naznačen time što farmaceutska formulacija sadrži 0.25-0.8% dapagliflozina ili dapagliflozin (S) propilen glikol hidrata; 62-77% metformin hidroklorida; 3-10% hidroksipropil celuloze; 5-21% mikrokristalne celuloze; 5-9% natrijevog škrob glikolata; i 0.6-1.4% magnezijevog stearata.
The method of claim 29, wherein the pharmaceutical formulation is 0.1-1% dapagliflozin or dapagliflozin (S) propylene glycol hydrate; 60-80% metformin hydrochloride; 1-10% hydroxypropyl cellulose; 2-25% microcrystalline cellulose; 4-10% sodium starch glycolate or 3-10% hydroxypropyl cellulose, low substituted; and 0.25-2.5% magnesium stearate. 
Postupak prema zahtjevu 29, naznačen time što farmaceutska formulacija sadrži 0.1-1% dapagliflozina ili dapagliflozin (S) propilen glikol hidrata; 60-80% metformin hidroklorida; 1-10% hidroksipropil celuloze; 2-25% mikrokristalne celuloze; 4-10% natrijevog škrob glikolata ili 3-10% hidroksipropil celuloze, nisko supstituirane; i 0.25-2.5% magnezijevog stearata.
the tablet core comprises 0.1-1% dapagliflozin or dapagliflozin (S) propylene glycol hydrate; 60-80% metformin hydrochloride; 1-10% hydroxypropyl cellulose; 2-25% microcrystalline cellulose; 4-10% sodium starch glycolate or 3-10% hydroxypropyl cellulose, low substituted; and 0.25-2.5% magnesium stearate; 
jezgra tablete sadrži 0.1-1% dapagliflozina ili dapagliflozin (S) propilen glikol hidrata; 60-80% metformin hidroklorida; 1-10% hidroksipropil celuloze; 2-25% mikrokristalne celuloze; 4-10% natrijevog škrob glikolata ili 3-10% hidroksipropil celuloze, nisko supstituirane; i 0.25-2.5% magnezijevog stearata;
a first coating that comprises a composition consisting of 40% polyvinyl alcohol, 20% polyethylene glycol, 15% talc, and 25% titanium dioxide; (3) a second coating that comprises saxagliptin and a composition consisting of 40% polyvinyl alcohol, 20% polyethylene glycol, 15% talc, and 25% titanium dioxide; and (4) a third coating that comprises a composition consisting of 40% polyvinyl alcohol, 20% polyethylene glycol, 15% talc, and 25% titanium dioxide. 
prvi premaz koji sadrži pripravak koji se sastoji od 40% polivinil alkohola, 20% polietilen glikola, 15% talka, i 25% titanijevog dioksida; (3) drugi premaz koji sadrži saksagliptin i pripravak koji se sastoji od 40% polivinil alkohola, 20% polietilen glikola, 15% talka, i 25% titanijevog dioksida; i (4) treći premaz koji sadrži pripravak koji se sastoji od 40% polivinil alkohola, 20% polietilen glikola, 15% talka, i 25% titanijevog dioksida.
the tablet core comprises: 
jezgra tablete sadrži:
0.5% dapagliflozin or dapagliflozin (S) propylene glycol hydrate; 70.5% metformin hydrochloride; 5.5% hydroxypropyl cellulose; about 20.5% microcrystalline cellulose; about 5% sodium starch glycolate; and about 1% magnesium stearate; 
0.5% dapagliflozina ili dapagliflozin (S) propilen glikol hidrata; 70.5% metformin hidroklorida; 5.5% hidroksipropil celuloze; oko 20.5% mikrokristalne celuloze; oko 5% natrijevog škrob glikolata; i oko 1% magnezijevog stearata;
about 0.5% dapagliflozin or dapagliflozin (S) propylene glycol hydrate; about 75.5% metformin hydrochloride; about 6% hydroxypropyl cellulose; 12.5% microcrystalline cellulose; 5% sodium starch glycolate; and 0.6% magnesium stearate; 
oko 0.5% dapagliflozina ili dapagliflozin (S) propilen glikol hidrata; oko 75.5% metformin hidroklorida; oko 6% hidroksipropil celuloze; 12.5% mikrokristalne celuloze; 5% natrijevog škrob glikolata; i 0.6% magnezijevog stearata;
A pharmaceutical combination that comprises a pharmaceutical formulation according to claim 1 and an anti-diabetic, wherein the anti-diabetic is a sulfonylurea, thiazolidinedione, alpha glucosidase inhibitor, meglitinide, glucagon-like peptide (GLP) agonist, insulin, amylin agonist, fructose 1,6-bis phosphatase inhibitor, insulin secretagogue, insulin sensitizer, glucokinase activator, glucocorticoid antagonist, AMP kinase activator, modulators of the incretin pathway such as incretin secretagogue, incretin mimic, incretin potentiator, bile acid sequestrant or bile acid receptor agonist such as TGR5 agonist, dopamine receptor agonist, aldose reductase inhibitor, PPARγ agonist, PPARa agonist, PPARδ antagonist or agonist, PPARa/γ dual agonist, 11-β-HSD-1 inhibitor, dipeptidyl peptidase IV (DPP4) inhibitor other than saxagliptin, SGLT2 inhibitor other than dapagliflozin, glucagon-like peptide-1 (GLP-1), GLP-1 agonist, or PTP-1B inhibitor. 
Farmaceutska kombinacija naznačena time da sadrži farmaceutsku formulaciju prema zahtjevu 1 i anti-dijabetičko sredstvo, pri čemu anti-dijabetičko sredstvo je sulfonilurea, tiazolidindion, inhibitor alfa glukozidaze, meglitinid, agonist glukagonu sličnog peptida (GLP), inzulin, agonist amilina, inhibitor fruktoza 1,6-bis fosfataze, sekretagog inzulina, senzitizator inzulina, aktivator glukokinaze, glukokortikoidni antagonist, aktivator AMP kinaze, modulatori inkretinskog puta kao što je sekretagog inkretina, mimetik inkretina, potencijator inkretina, sekvestrant žučne kiseline ili agonist receptora žučne kiseline kao što je agonist TGR5, agonist receptora dopamina, inhibitor aldoza reduktaze, PPARγ agonist, PPARa agonist, PPARδ antagonist ili agonist, PPARa/γ dual agonist, 11-β-HSD-1 inhibitor, inhibitor dipeptidil peptidaze IV (DPP4) različit od saksagliptina, inhibitor SGLT2 različit od dapagliflozina, glukagonu sličan peptid-1 (GLP-1), agonist GLP-1, ili inhibitor PTP-1B.
A pharmaceutical combination that comprises a pharmaceutical formulation according to claim 1 and a weight loss agent, wherein the weight loss agent is sibutramine, a CB1 antagonist, a 5HT2C agonist, a MCHR1 antagonist, Orlistat, a thyromimetic, an amylin mimetic, or a ghrelin antagonist. 
Farmaceutska kombinacija koja sadrži farmaceutsku formulaciju prema zahtjevu 1 i sredstvo za gubitak težine, pri čemu je sredstvo za gubitak težine sibutramin, antagonist CB1, agonist 5HT2C, antagonist MCHRl, Orlistat, tiromimetik, amilinski mimetik, ili antagonist grelina.
The container (100) as claimed in claim characterized in that the secondary skirt (138) is connected to the primary skirt (114) on either side of the lid lever (132). 
Spremnik (100) u skladu s patentnim zahtjevom, naznačen time što je sekundarni obod (138) spojen s primarnim obodom (114) na obje strane poluge poklopca (132).
The container (100) as claimed in claim 11, characterized in that the ribs of the set of ribs (144) of the secondary skirt (138) are offset from the first and second cuts (120,130). 
Spremnik (100) u skladu s patentnim zahtjevom 11, naznačen time što su rebra iz skupa rebara (144) sekundarnog oboda (138) smještena s odmakom u odnosu na prvi i drugi urez (120,130).
A composition comprising at least one biological control agent which is Bacillus subtilis AQ713 (NRRL Accession No. 
Pripravak koji sadrži barem jedno biološko kontrolno sredstvo koje je Bacillus subtilis AQ713 (NRRL Pristupni br.
Kit of parts comprising at least one biological control agent which is Bacillus subtilis AQ713 (NRRL Accession No. 
Komplet dijelova koji sadrži barem jedno biološko kontrolno sredstvo koje je Bacillus subtilis AQ713 (NRRL Pristupni br.